The FDA database lists a supplement dated 19 October 2026 to abbreviated new drug application 211598 for voriconazole, held by Hetero Labs, an Indian manufacturer. A supplement to a generic application usually covers manufacturing, labelling or packaging changes rather than a new use.
No new safety information or indication is attached. The relevance for Indian prescribers is mainly that generic voriconazole supply from Indian manufacturers continues to meet US regulatory requirements.
Voriconazole remains a drug that rewards attention: levels vary widely with CYP2C19 genotype, liver function and interacting drugs, and both toxicity and failure track with trough concentration.
- Check voriconazole trough levels after about five days where testing is available
- Review interactions with rifampicin, carbamazepine, some HIV drugs and statins before starting
- Monitor liver function and ask about visual disturbance and photosensitivity
- Switch to another azole if levels cannot be kept in range
Why it matters
Nothing changes at the bedside, but the drug itself still needs close monitoring.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free